Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.59 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.52 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.52 |
| ▸ | AMD1 | P17707 | 2/20 | 0.48 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.47 |
| ▸ | AHCY | P23526 | 3/20 | 0.43 |
| ▸ | MARS1 | P56192 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060720 | 0.90 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL5060725 | 0.90 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL26530697 | 0.90 | PI4KA (0.55) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL14174710 | 0.86 | PI4KA (0.58) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL17777367 | 0.85 | DOT1L (0.61) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL19711692 | 0.85 | PI4KA (0.57) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL2291899 | 0.83 | PI4KA (0.69) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL2291893 | 0.81 | PI4KA (0.67) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL13662859 | 0.81 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBRXFP1 | |
| SCHEMBL14703568 | 0.81 | PI4KA (0.71) | PI4KAPI4K2BPI4K2API4KBRXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | METHYLGENE INC. (CA) | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132525-A1 | isoforms DNMT1 and DNMT3b2; for example: 2-amino-4-(((2S,3S,4R,5R)-3,4-dihydroxy-5-(6-(phenethylamino)-9H-purin-9-yl)-tetrahydrofuran-2-yl)methylthio)butanoic acid | DNMT3B, DNMT1, DNMT3L | PI4KA 2879/4885PI4K2B 2005/4885PI4K2A 2640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.